DON HUSEREAU travaille avec des organisations des sciences de la vie des secteurs privé et public pour les aider à comprendre la valeur des technologies de la santé et leurs implications pour la politique de la santé et de l'innovation. Il est l'auteur de nombreux travaux sur le rôle et la valeur de l'innovation, notamment des rapports commandés par la Commission fédérale sur l'innovation de Santé Canada (la Commission Naylor), l'Institut canadien d'information sur la santé, Santé Canada, l'Institut CD Howe et l'Agence canadienne des médicaments et des technologies de la santé. Il est actuellement président d'un groupe de travail international qui a élaboré des normes consolidées pour les rapports d'évaluation économique de la santé (CHEERS) qui sont désormais approuvées par les principales revues biomédicales et de politique de la santé. En tant qu'expert en économie de la santé et en évaluation des technologies de la santé, Don est actuellement conseiller éditorial pour les revues biomédicales Pharmacoeconomics et BMC Medicine. Il est également associé principal de l'Institute of Health Economics de l'Alberta.
Selected Publications (past 5 years)
Staniszewska S, Jakab I, Low E, Mossman J, Posner P, Husereau D, et al. Commentary: Advocating for patient and public involvement and engagement in health economic evaluation. Res Involv Engagem. 2023;9:45.
Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, et al. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Curr Oncol. 2023;30:3776–86.
Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, et al. A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. Value Health. 2023;26:185–92.
Oortwijn W, Husereau D, Abelson J, Barasa E, Bayani DD, Canuto Santos V, et al. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. Value Health. 2022;25:869–86.
Kunst N, Siu A, Drummond M, Grimm SE, Grutters J, Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration. Value Health. 2023;26:1461–73.
Husereau D, Villalba E, Muthu V, Mengel M, Ivany C, Steuten L, et al. Progress toward Health System Readiness for Genome-Based Testing in Canada. Curr Oncol. 2023;30:5379–94.
Husereau D, Sullivan T, Feilotter HE, Gomes MM, Juergens R, Sheffield BS, et al. Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. J Med Econ. 2022;25:993–1004.
Husereau D, Steuten L, Muthu V, Thomas DM, Spinner DS, Ivany C, et al. Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness? Healthcare (Basel). 2022;10:2086.
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Appl Health Econ Health Policy. 2022;20:781–2.
Culyer A, Husereau D. Redefining Health Technology Assessment: A Comment on “The New Definition of Health Technology Assessment: A Milestone in International Collaboration.” Int J Technol Assess Health Care. 2022;38:e54.
Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658-665. doi:10.1038/s41591-022-01717-2
Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics. 2022;40(6):601-609. doi:10.1007/s40273-021-01112-8
Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10-31. doi:10.1016/j.jval.2021.10.008
Augustovski F, García Martí S, Espinoza MA, Palacios A, Husereau D, Pichon-Riviere A. Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: adaptación al español de la lista de comprobación CHEERS 2022. Value Health Reg Issues. 2022;27:110-114. doi:10.1016/j.vhri.2021.11.001
Zoratti MJ, Pickard AS, Stalmeier PFM, et al. Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. Eur J Health Econ. 2021;22(5):723-733. doi:10.1007/s10198-021-01286-0
Thanh NX, Jacobs P, Husereau D. Gross profits of Canadian pharmacies: A changing policy regime. Healthc Manage Forum. 2020;33(5):228-232. doi:10.1177/0840470420932185
Patel YP, Husereau D, Leighl NB, Melosky B, Nam J. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. Curr Oncol. 2021;28(6):5278-5294. doi:10.3390/curroncol28060441
Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, Bond K, et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value Health. 2019;22(1):13–20.
Jetty P, Husereau D, Kansal V, Zhang T, Nagpal S. Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario. J Vasc Surg. 2019 Nov;70(5):1469–78.
Husereau D, Reed SD. A Beginner’s Guide to Understanding Curative Therapies. Value Health. 2019;22(6):619–20.
Husereau D, Nason E, Ahuja T, Nikaï E, Tsakonas E, Jacobs P. Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. Int J Technol Assess Health Care. 2019 Jan;35(3):181–8